CBLC

Across TCGA pan-cancer cohorts, CBLC Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CBLC data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CBLC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CBLC expression acts as an unfavorable survival marker.

THYM, CESC, and OV are the cancer types where CBLC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
CESC	DFS	Median	All	0.379	0.826	<.001	36	view →
OV	OS	Median	II,III,IV	0.308	0.691	.033	18	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	14	view →
LIHC	OS	Median	All	0.098	0.774	.001	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CBLC–THYM (OS)

Open the THYM breakdown →